Helius Pharma appoints Michael Halstead as chief executive officer to lead its next phase of growth in cannabinoid-derived pharmaceutical development and commercialization

Helius Pharma has appointed Michael Halstead as chief executive officer, signaling a leadership change aimed at advancing the company's cannabinoid-derived pharmaceutical business. The move centers on scaling commercial execution, corporate strategy, and the development pipeline. Helius Pharma operates in the regulated medicinal cannabis and cannabinoid medicines space, so the appointment matters as part of a broader effort to strengthen management capacity during growth. Leadership transitions of this kind often indicate a focus on operational expansion, market positioning, and the path from product development to commercialization. Michael Halstead's role is likely to shape how the company pursues partnerships, regulatory progress, and competitive differentiation in the cannabis-based pharmaceutical sector.